$CVAT
Cavitation Technologies, Inc. Stock $cvat

$cvat Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168316823003267 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$52.00K	$61.00K	$38.00K
YoY Change	-94.6%	60.53%	-74.32%
Cost Of Revenue	$48.00K	$11.00K	$16.00K
YoY Change	-4900.0%	-31.25%	433.33%
Gross Profit	$4.000K	$50.00K	$22.00K
YoY Change	-99.59%	127.27%	-84.83%
Gross Profit Margin	7.69%	81.97%	57.89%
Selling, General & Admin	$323.0K	$273.0K	$270.0K
YoY Change	-46.7%	1.11%	-5.26%
% of Gross Profit	8075.0%	546.0%	1227.27%
Research & Development	$3.000K	$0.00	$14.00K
YoY Change	200.0%	-100.0%
% of Gross Profit	75.0%	0.0%	63.64%
Depreciation & Amortization	$2.000K	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit	50.0%	0.0%	0.0%
Operating Expenses	$326.0K	$273.0K	$284.0K
YoY Change	-46.29%	-3.87%	-0.35%
Operating Profit	-$322.0K	-$223.0K	-$262.0K
YoY Change	-190.2%	-14.89%	87.14%
Interest Expense	-$1.108M	$1.000K	$35.00K
YoY Change	1203.53%	-97.14%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$371.0K
YoY Change		-100.0%
Pretax Income	-$1.430M	-$238.0K	-$598.0K
YoY Change	-1621.28%	-60.2%	327.14%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.430M	-$238.0K	-$598.0K
YoY Change	-1621.28%	-60.2%	327.14%
Net Earnings / Revenue	-2750.0%	-390.16%	-1573.68%
Basic Earnings Per Share		$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	-$2.226K
COMMON SHARES
Basic Shares Outstanding	282.2M shares	276.7M shares	268.6M shares
Diluted Shares Outstanding		277.8M shares	268.6M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.00K	$310.0K	$779.0K
YoY Change	-95.92%	-60.21%	-7.04%
Cash & Equivalents	$18.00K	$310.0K	$779.0K
Short-Term Investments
Other Short-Term Assets	$0.00	$0.00
YoY Change	-100.0%
Inventory	$0.00	$48.00K	$50.00K
Prepaid Expenses	$0.00	$0.00
Receivables	$0.00	$0.00	$36.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$18.00K	$358.0K	$865.0K
YoY Change	-96.59%	-58.61%	-15.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000K	$3.000K	$379.0K
YoY Change	-75.0%	-99.21%	-14.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.000K	$1.106M	$1.260M
YoY Change	-99.91%	-12.22%
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$125.0K	$1.249M	$1.649M
YoY Change	-90.69%	-24.26%	262.42%
TOTAL ASSETS
Total Short-Term Assets	$18.00K	$358.0K	$865.0K
Total Long-Term Assets	$125.0K	$1.249M	$1.649M
Total Assets	$143.0K	$1.607M	$2.514M
YoY Change	-92.36%	-36.08%	70.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$120.0K	$129.0K	$97.00K
YoY Change	-11.11%	32.99%	-67.77%
Accrued Expenses	$348.0K	$343.0K	$341.0K
YoY Change	1.46%	0.59%	-52.77%
Deferred Revenue	$391.0K	$443.0K
YoY Change	388.75%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000K
YoY Change
Total Short-Term Liabilities	$864.0K	$915.0K	$1.477M
YoY Change	54.84%	-38.05%	-11.13%
LONG-TERM LIABILITIES
Long-Term Debt	$145.0K	$150.0K	$150.0K
YoY Change	-3.33%	0.0%	-58.1%
Other Long-Term Liabilities	$53.00K	$76.00K	$145.0K
YoY Change	-58.27%	-47.59%	-31.92%
Total Long-Term Liabilities	$145.0K	$150.0K	$295.0K
YoY Change	-47.65%	-49.15%	-48.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$864.0K	$915.0K	$1.477M
Total Long-Term Liabilities	$145.0K	$150.0K	$295.0K
Total Liabilities	$1.062M	$1.141M	$1.772M
YoY Change	27.19%	-35.61%	-20.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.29M	-$25.86M
YoY Change	8.08%
Common Stock	$284.0K	$279.0K
YoY Change	2.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$919.0K	$466.0K	$742.0K
YoY Change
Total Liabilities & Shareholders Equity	$143.0K	$1.607M	$2.514M
YoY Change	-92.36%	-36.08%	70.67%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.430M	-$238.0K	-$598.0K
YoY Change	-1621.28%	-60.2%	327.14%
Depreciation, Depletion And Amortization	$2.000K	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$292.0K	-$33.00K	-$277.0K
YoY Change	-13.61%	-88.09%	75.32%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$44.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$44.00K
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-292.0K	-33.00K	-277.0K
Cash From Investing Activities	0.000	0.000	-44.00K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-292.0K	-33.00K	-321.0K
YoY Change	-13.61%	-89.72%	494.44%
FREE CASH FLOW
Cash From Operating Activities	-$292.0K	-$33.00K	-$277.0K
Capital Expenditures	$0.00	$0.00	-$44.00K
Free Cash Flow	-$292.0K	-$33.00K	-$233.0K
YoY Change	-13.61%	-85.84%	47.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001376793
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Entity File Number EntityFileNumber	000-53239
	dei	Entity Registrant Name EntityRegistrantName	Cavitation Technologies, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4907818
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10019 CANOGA AVENUE
	dei	Entity Address City Or Town EntityAddressCityOrTown	CHATSWORTH
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91311
	dei	City Area Code CityAreaCode	(818)
	dei	Local Phone Number LocalPhoneNumber	718-0905
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	282235384	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	441000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	48000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	48000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	358000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	528000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4000	usd
CY2023Q1	us-gaap	Equity Method Investments EquityMethodInvestments	1106000	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1149000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	130000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	10000	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	10000	usd
CY2023Q1	us-gaap	Assets Assets	1607000	usd
CY2022Q2	us-gaap	Assets Assets	1871000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	129000	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	135000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	280000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	443000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	80000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	915000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	558000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150000	usd
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	150000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	127000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1141000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	835000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	278698831	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	278698831	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	276698831	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	276698831	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	279000	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	277000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26043000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26005000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25856000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25246000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	466000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1036000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1607000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1871000	usd
CY2023Q1	us-gaap	Revenues Revenues	61000	usd
CY2022Q1	us-gaap	Revenues Revenues	38000	usd
	us-gaap	Revenues Revenues	381000	usd
	us-gaap	Revenues Revenues	702000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	11000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	73000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	26000	usd
CY2023Q1	CVAT	Cost Of Revenue Joint Venture CostOfRevenueJointVenture	-0	usd
CY2022Q1	CVAT	Cost Of Revenue Joint Venture CostOfRevenueJointVenture	16000	usd
	CVAT	Cost Of Revenue Joint Venture CostOfRevenueJointVenture	-0	usd
	CVAT	Cost Of Revenue Joint Venture CostOfRevenueJointVenture	16000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	50000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	22000	usd
	us-gaap	Gross Profit GrossProfit	308000	usd
	us-gaap	Gross Profit GrossProfit	660000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	273000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	270000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	872000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1122000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	0	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	273000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	284000	usd
	us-gaap	Operating Expenses OperatingExpenses	872000	usd
	us-gaap	Operating Expenses OperatingExpenses	1138000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-223000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-262000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-564000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-478000	usd
CY2023Q1	CVAT	Loss From Settlement Of Liabilities LossFromSettlementOfLiabilities	0	usd
CY2022Q1	CVAT	Loss From Settlement Of Liabilities LossFromSettlementOfLiabilities	-371000	usd
	CVAT	Loss From Settlement Of Liabilities LossFromSettlementOfLiabilities	0	usd
	CVAT	Loss From Settlement Of Liabilities LossFromSettlementOfLiabilities	-371000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	104000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-14000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	37000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	37000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	2000	usd
	us-gaap	Interest Expense InterestExpense	3000	usd
	us-gaap	Interest Expense InterestExpense	5000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-238000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-598000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-610000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-713000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	277809942	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	277809942	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	268618159	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	268618159	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	277063795	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	277063795	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	239868345	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	239868345	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	664000	usd
CY2023Q1	CVAT	Fair Value Of Common Stock Granted For Services FairValueOfCommonStockGrantedForServices	40000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-238000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	466000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1036000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	40000	usd
	us-gaap	Profit Loss ProfitLoss	-610000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	466000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	378000	usd
CY2022Q1	CVAT	Common Stock Issued Upon Exercise Of Warrants CommonStockIssuedUponExerciseOfWarrants	7000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2022Q1	CVAT	Fair Value Of Common Stock Granted To Settle Liabilities FairValueOfCommonStockGrantedToSettleLiabilities	930000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-598000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	742000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-411000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	785000	usd
	CVAT	Common Stock Issued Upon Exercise Of Warrants CommonStockIssuedUponExerciseOfWarrants	77000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	usd
	CVAT	Fair Value Of Common Stock Granted To Settle Liabilities FairValueOfCommonStockGrantedToSettleLiabilities	930000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	40000	usd
	CVAT	Fair Value Of Common Stock Granted For Services FairValueOfCommonStockGrantedForServices	25000	usd
	us-gaap	Profit Loss ProfitLoss	-713000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	742000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-610000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-713000	usd
	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Depreciation Depreciation	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	40000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	151000	usd
	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	0	usd
	CVAT	Loss On Settlement Of Liabilities LossOnSettlementOfLiabilities	371000	usd
	CVAT	Income Loss From Equity Method Investments1 IncomeLossFromEquityMethodInvestments1	-43000	usd
	CVAT	Income Loss From Equity Method Investments1 IncomeLossFromEquityMethodInvestments1	37000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	104000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25000	usd
	CVAT	Increase Decrease In Operating Lease Asset IncreaseDecreaseInOperatingLeaseAsset	50000	usd
	CVAT	Increase Decrease In Operating Lease Asset IncreaseDecreaseInOperatingLeaseAsset	48000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-30000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-44000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	363000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	312000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-51000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-45000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-38000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-146000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	-0	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	1223000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1223000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	785000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	785000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-131000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-584000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	441000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1363000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	779000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	CVAT	Issuance Of Note Payable To Settle Accrued Payroll And Liability Related Party IssuanceOfNotePayableToSettleAccruedPayrollAndLiabilityRelatedParty	0	usd
	CVAT	Issuance Of Note Payable To Settle Accrued Payroll And Liability Related Party IssuanceOfNotePayableToSettleAccruedPayrollAndLiabilityRelatedParty	559000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-610000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131000	usd
CY2023Q1	CVAT	Working Capital WorkingCapital	-557000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	310000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_z5gMMLAxi4V1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_864_zu5SD579ABt5">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in reserve for inventory obsolescence, impairment analysis for property and equipment, accrual of potential liabilities, deferred tax assets and valuing our stock options, warrants, and common stock issued for services, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zxfOapOTCVD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zagfFyKE3Z1j">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash - cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts payable and accrued expenses – three vendors accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zE8xD359Vzk4" title="Concentration Risk, Percentage">33</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__srt--MajorCustomersAxis__custom--SecondVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zuDTTpfmhR2d" title="Concentration Risk, Percentage">29</span>%, and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__srt--MajorCustomersAxis__custom--ThirdVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgT9gx5IpNW1" title="Concentration Risk, Percentage">26</span>% of accounts payable and accrued expenses as of March 31, 2023. Three vendors accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__srt--MajorCustomersAxis__custom--OneVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zoaxAC4gx0Ka" title="Concentration Risk, Percentage">32</span>%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__srt--MajorCustomersAxis__custom--SecondVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zu0pOhdNtRE" title="Concentration Risk, Percentage">29</span>% and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__srt--MajorCustomersAxis__custom--ThirdVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zFmxnTjNgz6k" title="Concentration Risk, Percentage">24</span>% of accounts payable and accrued expenses as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues – during the three and nine month periods ended March 31, 2023 <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zA94RoOBntvg" title="Concentration Risk, Percentage"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7wss6BbuVyc" title="Concentration Risk, Percentage">95</span></span>% for both periods presented, were from Desmet. Revenue during the three and nine months periods ended March 31, 2022 were <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziz13SnUVTKj" title="Concentration Risk, Percentage">100</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220331__srt--MajorCustomersAxis__custom--DesmetMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQUZsgPMsZ21" title="Concentration Risk, Percentage">94</span>% of revenues, respectively, were from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Operating Lease Cost OperatingLeaseCost	57000	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	57000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.04	pure
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	130000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	63000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	139000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	78000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	53000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	150000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	139000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	280000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	280000	usd

Files In Submission

Name	View Source	Status
cvat-20230331_cal.xml	Edgar Link	unprocessable
0001683168-23-003267-index-headers.html	Edgar Link	pending
0001683168-23-003267-index.html	Edgar Link	pending
0001683168-23-003267.txt	Edgar Link	pending
0001683168-23-003267-xbrl.zip	Edgar Link	pending
cavitation_ex3101.htm	Edgar Link	pending
cavitation_ex3102.htm	Edgar Link	pending
cavitation_ex3201.htm	Edgar Link	pending
cavitation_ex3202.htm	Edgar Link	pending
cavitation_i10q-033123.htm	Edgar Link	pending
cvat-20230331.xsd	Edgar Link	pending
cavitation_i10q-033123_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvat-20230331_def.xml	Edgar Link	unprocessable
cvat-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvat-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVAT
Cavitation Technologies, Inc. Stock $cvat

2023 Q2 Form 10-Q Financial Statement

#000168316823003267 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT Cavitation Technologies, Inc. Stock $cvat

2023 Q2 Form 10-Q Financial Statement

#000168316823003267 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVAT
Cavitation Technologies, Inc. Stock $cvat